The research of the effectiveness and the safety in the treatment of patients with the non-bacterial chronic prostatitis

Keywords

chronic abacterial prostatitis
rectal suppository Vitaprost
Vitaprost Forte
treatment хронический абактериальный простатит
ректальные суппозитории
Витапрост
Витапрост Форте
лечение хронічний абактеріальний простатит
ректальні супозиторії
Вітапрост
Вітапрост Форте
лікування

Abstract

The aim of the study: to study the efficacy and safety of rectal suppositories Vitaprost and Vitaprost Forte in the treatment of patients with chronic abacterial prostatitis. Materials and methods. The study included 75 patients with chronic abacterial prostatitis. The average age of the patients was 28.2±3.5 years (19 to 45 years), disease duration from 8 months to 5 years (mean 3.2±1.2 years). Depending on the methods of therapy, the patients were divided into three groups. Patients of the 1st group (n=25) received the standard treatment according to the Protocol. In therapy, patients of the 2nd group (n=25) were included rectal suppositories Vitaprost («STADA»). Patients of the 3rd group (n=25) in the complex treatment received rectal suppositories Vitaprost Forte. All three groups of patients were matched for diagnosis and age. Results. Control survey after completion of therapy, confirmed the disappearance of the inflammatory process in the pancreas. Patients reported a significant decrease in subjective symptoms, often with complete disappearance of pain syndrome, and significant improvement in General condition and copulative functions. These data were the best in patients of the 3rd group. Conclusion. The appointment of rectal suppositories Vitaprost and Vitaprost Forte pathogenetically grounded for chronic abacterial prostatitis, which allows achieving the positive results of the therapy and persistent clinical effect. Patients of the 3rd group who received therapy with suppositories Vitaprost Forte had the best results in comparison with patients of the 2nd group, which proves the dependence of the degree of effect of the dose of active substance – Sampras.
https://doi.org/10.30841/2307-5090.2(57).2016.82964
PDF (Українська)

References

Горпинченко І.І., Литвинець Є.А. Сучасні підходи та шляхи оптимізації лікування хворих на хронічний простатит //Здоровье мужчины. – 2007. – № 3. – С. 48–56.

Горпинченко И.И., Клименко П.М., Павловський Ю.Э. Гемодинамическая классификация простатитов //Здоровье мужчины. – 2004. – № 1. – С. 44–48.

Литвинець Є.А. Ехінацея: фармакологічні та лікувальні властивості // Галицький лікарський вісник. – 2000. – № 4. – С. 150–151.

Литвинець Є.А., Костенко Л.В. Кольорова ультразвукова ангіографія в діагностиці хронічного простатиту //Галицький лікарський вісник. – 2006. – № 1. – С. 40–42.

Молочков В.А., Ильин И.И. Хронический уретрогенный простатит. – М.: Медицина, 1998. – 303 с.

Практическое руководство по ультразвуковой диагностике / Под ред. Митькова В.В. – М.: Издательский дом Видар-М, 2003. – 720 с.

Ткачук В.Н., Горбачев А.Г., Агулянский Л.И. Хронический простатит. – Л.: Медицина, 1989. – 208 c.

Hong SJ. and al. Transrectal color Doppler imaging is effective for the posttreatment monitoring of prostatic inflammation // J. Urol. – 1996. – V. 155. – P. 480–488.

Veneziano S., Pavlica P., Mannini D. Color Doppler ultrasonographic scanning in prostatitis: сlinical correlation // Eur. Urol. – 1995. – V. 28, № 1. – Р. 6–9.

Neikel I.C., Downey L, Dark I., Ceri H., Olson M. Antibiotic pharmacokinetics in the inflamed prostate // Journal of Urology. – 1995. – V. 153, № 2. – P. 527–529.

Ghobich A. Voiding dysfunction associated with chronic bacterial prostatitis. Eur. Urol. – 2002; 42: 159–162.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2020 Є. А. Литвинець, О. П. Сандурський, В. I. Тріщ, А. Кабіру